What does CUSIP 68235C107 represent in this 13F holders report?

CUSIP 68235C107 is the security identifier for OCX - Oncocyte Corporation - Common Shares, No Par Value used to aggregate holder disclosures.

How many institutions held OCX - Oncocyte Corporation - Common Shares, No Par Value in Q4 2023?

2 institutional investors reported OCX - Oncocyte Corporation - Common Shares, No Par Value for Q4 2023. Use the holders table for investor-level position and value details.

Oncocyte Corporation - Common Shares, No Par Value (OCX)

CUSIP: 68235C107

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class: Equity / Common Shares, No Par Value
Shares outstanding: 28,495,649
Total 13F shares: 825,936
Share change: -7,866
Total reported value: $2,049,754
Price per share: $2.49
Number of holders: 2
Value change: -$20,365
Number of buys: 1
Number of sells: 1

Quarterly Holders Quick Answers

What is CUSIP 68235C107?
CUSIP 68235C107 identifies OCX - Oncocyte Corporation - Common Shares, No Par Value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2024
Previous quarter: Q3 2023

Recent filing periods for CUSIP 68235C107:

Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023

Top shareholders of OCX - Oncocyte Corporation - Common Shares, No Par Value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BROADWOOD CAPITAL INC	13F	Company	7.8%	2,509,066	$7,828,286	—	30 Sep 2023	13F
PURA VIDA INVESTMENTS, LLC	3/4/5 13F	10%+ Owner · Company	2% from 13F	16,591,052 mixed-class rows	$3,044,309	—	14 Apr 2023	3/4/5 13F
AWM Investment Company, Inc.	13F	Company	2.5%	719,282	$2,359,245	—	30 Sep 2023	13F
VANGUARD GROUP INC	13F	Company	0.74%	240,089	$749,078	—	30 Sep 2023	13F
MORGAN STANLEY	13F	Company	0.43%	139,538	$435,359	—	30 Sep 2023	13F
Defender Capital, LLC.	13F	Company	0.4%	114,520	$357,302	—	30 Sep 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.19%	61,482	$201,727	—	30 Sep 2023	13F
BlackRock Finance, Inc.	13F	Company	0.19%	60,293	$188,114	—	30 Sep 2023	13F
John Peter Gutfreund	3/4/5	Former Director	— mixed-class rows	760,000 mixed-class rows	$153,654	—	30 Jun 2023	3/4/5
Ronald Asbury Andrews	3/4/5	Former CEO, Director	— mixed-class rows	633,212 mixed-class rows	$125,332	—	01 Dec 2022	3/4/5
Alfred D. Kingsley	3/4/5	Director	— mixed-class rows	597,878 mixed-class rows	$109,143	—	23 Jun 2023	3/4/5
Gisela Paulsen	3/4/5	Former President and COO	— class O/S missing	366,500	$78,761	—	16 Dec 2022	3/4/5
Li Yu	3/4/5	VP Cntrllr/Prncpl Acctng Offcr	— mixed-class rows	41,872 mixed-class rows	$76,536	—	18 May 2022	3/4/5
STATE STREET CORP	13F	Company	0.05%	16,289	$53,428	—	30 Sep 2023	13F
Ross Douglas T.	3/4/5	Former CSO	— class O/S missing	234,114	$50,311	—	21 Dec 2022	3/4/5
MILLENNIUM MANAGEMENT LLC	13F	Company	0.05%	14,754	$48,393	—	30 Sep 2023	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.04%	12,218	$38,000	—	30 Sep 2023	13F
Cavan M. Redmond	3/4/5	Director	— class O/S missing	120,863	$25,973	—	24 Jun 2022	3/4/5
Mitchell S. Levine	3/4/5	Chief Financial Officer	— mixed-class rows	174,580 mixed-class rows	$18,713	—	15 Mar 2022	3/4/5
Tower Research Capital LLC (TRC)	13F	Company	0.01%	2,556	$7,975	—	30 Sep 2023	13F
Jennifer Levin Carter	3/4/5	Director	— mixed-class rows	75,500 mixed-class rows	$6,554	—	15 Aug 2022	3/4/5
Melinda Griffith	3/4/5	Director	— mixed-class rows	75,000 mixed-class rows	$6,447	—	15 Aug 2022	3/4/5
OSAIC HOLDINGS, INC.	13F	Company	0%	1,266	$3,950	—	30 Sep 2023	13F
UBS Group AG	13F	Company	0%	1,025	$3,198	—	30 Sep 2023	13F
ROYAL BANK OF CANADA	13F	Company	0%	1,019	$3,000	—	30 Sep 2023	13F
PNC FINANCIAL SERVICES GROUP, INC.	13F	Company	0%	500	$1,560	—	30 Sep 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	210	$655	—	30 Sep 2023	13F
JPMORGAN CHASE & CO	13F	Company	0%	154	$505	—	30 Sep 2023	13F
RHUMBLINE ADVISERS	13F	Company	0%	66	$216	—	30 Sep 2023	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	58	$181	—	30 Sep 2023	13F
Riggs Asset Managment Co. Inc.	13F	Company	0%	50	$156	—	30 Sep 2023	13F
COMERICA BANK	13F	Company	0%	37	$116	—	30 Sep 2023	13F
US BANCORP \DE\	13F	Company	0%	25	$78	—	30 Sep 2023	13F
Piscataqua Savings Bank	13F	Company	0%	25	$77	—	30 Sep 2023	13F
MEEDER ASSET MANAGEMENT INC	13F	Company	0%	9	$28	—	30 Sep 2023	13F
ALBION FINANCIAL GROUP /UT	13F	Company	0%	7	$22	—	30 Sep 2023	13F
Lindbrook Capital, LLC	13F	Company	0%	4	$12	—	30 Sep 2023	13F
Qube Research & Technologies Ltd	13F	Company	0%	1	$3	—	30 Sep 2023	13F
Anish M. John	3/4/5	Chief Financial Officer	— class O/S missing	121,381	—	—	24 Feb 2023	3/4/5
Padmavathi Sundar	3/4/5	Chief Commercial Officer	— class O/S missing	87,500	—	—	15 Mar 2022	3/4/5

Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q4 2023

As of 31 Dec 2023, Oncocyte Corporation - Common Shares, No Par Value (OCX) was held by 2 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 825,936 shares. The largest 2 holders included AWM Investment Company, Inc. and Defender Capital, LLC.. This page lists 2 institutional shareholders reporting positions in this security for the Q4 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2023 vs Q3 2023 Across Filers

Q3 2023 holders

Q4 2023 holders

Holder diff

Investor	Q3 2023 Shares	Q4 2023 Shares	Share Diff	Share Chg %	Q3 2023 Value $	Q4 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.